Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92427 citas

 
 
 1 a 20 de 32 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]
3. Cita con resumen
Damen NL, Baines R, Wagner C, Langelaan M. Medication-related adverse events during hospitalization: a retrospective patient record review study in The Netherlands. Pharmacoepidemiol Drug Saf 2017;26:32-9. [Ref.ID 101947]
4. Cita con resumen
Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol 2017;73:759-70. [Ref.ID 101675]
5. Cita con resumen
Anónimo. Corticosteroids: musculoskeletal adverse events. New Zealand. WHO Drug Information 2013;27:20-1. [Ref.ID 95294]
6. Cita con resumen
Hakkarainen KM, Alström D, Hägg S, Carlsten A, Gyllensten H. Modelling drug-related morbidity in Sweden using an expert panel pf physicians. Eur J Clin Pharmacol 2012;68:1309-19. [Ref.ID 93648]
7. Cita con resumen
Lövborg H, Eriksson LR, Jönsson AK, Bradley T, Hägg S. A prospective analysis of the preventability of adverse drug reactions reported in Sweden. Eur J Clin Pharmacol 2012;68:1183-9. [Ref.ID 93517]
8. Cita con resumen
Hakkarainen KM, Hedna K, Petzold M, Hägg S. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions - A meta-analysis. PLOS ONE 2012;7:e33236. [Ref.ID 92107]
9. Cita con resumen
Olivier P, Montastruc J-L. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf 2006;15:808-12. [Ref.ID 88737]
10. Cita con resumen
Jönsson AK, Hakkarainen KM, Spigset O, Druid H, Hiselius A, Hägg S. Preventable drug related mortality in a Swedish population. Pharmacoepidemiol Drug Saf 2010;19:211-5. [Ref.ID 87697]
11. Cita con resumen
Trinh-Duc A, Doucet J, Bannwarth B, Trombert-Paviot B, Carpentier F, Bouget J, Queneau P, et au nom de l'Association Pédagogique Nationale pour l'Enseignement de la Thérapeutique (APNET). Admissions des sujets âgés aux Services d'Accueil des Urgences pour effets indésirables médicamenteux. Therapie 2007;62:437-41. [Ref.ID 81068]
12. Cita con resumen
Day RO, Williams KM. Open-label extension studies: do they provide meaningful information on the safety of new drugs?. Drug Saf 2007;30:93-105. [Ref.ID 79290]
13.Tiene citas relacionadas Cita con resumen
Wardle EN. COX-2 inhibitors and risk of heart failure. Lancet 2004;364:1487. [Ref.ID 71718]
14.Tiene citas relacionadas Cita con resumen
Mamdani M, Juurlink D, Laupacis A, for the study research group. COX-2 inhibitors and risk of heart failure. Authors' reply. Lancet 2004;364:1487. [Ref.ID 71717]
15.Tiene citas relacionadas Cita con resumen
Kammerl MC, Debler J, Riegger G A, Krämer BK. COX-2 inhibitors and risk of heart failure. Lancet 2004;364:1486-7. [Ref.ID 71716]
16. Cita con resumen
Mjörndal T, Boman MD, Hägg S, Bäckström M, Wiholm BE, Wahlin A, Dahlqvist R. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 2002;11:65-72. [Ref.ID 61318]
19. Cita con resumen
Otero López MJ, Bajo Bajo A, Maderuelo JA, Domínguez-Gil Hurlé A. Evitabilidad de los acontecimientos adversos inducidos por medicamentos detectados en un servicio de Urgencias. Rev Clin Esp 1999;199:796-805. [Ref.ID 48524]
Seleccionar todas
 
 1 a 20 de 32 siguiente >>